Tugce I. Pasa

Also affiliated with Mayo Clinic in Arizona

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma”.

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0244

N/A

0.165DataRank · unranked

2 citations

Wenjuan Zhang, Ju-Hee Oh, Ann C. Mladek, Tugce I. Pasa, Jennifer Gantchev +24 more

Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0426

N/A

0DataRank · unranked

30 citations

Jessica I. Griffith, Kendra A. Porath, Sneha Rathi, Jiayan Le, Tugce I. Pasa +14 more

Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2012

N/A

0DataRank · unranked

0 citations

Wenjuan Zhang, Ann C. Mladek, Tugce I. Pasa, Katie L. Waller, Sylwia A. Stopka +15 more

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

Neuro-Oncology Advances(2025)10.1093/noajnl/vdaf259

N/A

0DataRank · unranked

0 citations

Wenjuan Zhang, Nishika Karbhari, Ju-Hee Oh, Katie L. Waller, Ann C. Mladek +16 more